Alana Hippensteele is lead editor at Pharmacy Times®, Contemporary Clinic, and Pharmacy Times Oncology Edition®. She has a master's in Critical Theory and Creative Research from Pacific Northwest College of Art and a bachelor's degree in English and Art History. She has worked as an English instructor at Temple University and held editorial positions at American Cleaning & Hygiene and Tin House.
In preliminary data from the trial evaluating dostarlimab, the results demonstrated that the clinical activity in patients with previously treated recurrent or advanced mismatch repair (MMR)-deficient endometrial cancer had an acceptable safety profile.
The new expanded approval was based on positive results from the phase 3 E1912 study.
Treatment of ovarian cancer with poly (ADP-ribose) polymerase (PARP) inhibitors has a high out-of-pocket cost for patients, with substantial variation among them, according to a study.
Obesity increases the risk of developing type 2 diabetes by at least 6 times, regardless of genetic predisposition, according to a recent study.
A phase 3 trial evaluated nivolumab in combination with ipilimumab in patients with previously untreated MPM and successfully met its primary endpoint of overall survival.
The phase 3 trial evaluating nivolumab in combination with cabozantinib demonstrated positive results in the treatment of renal cell carcinoma (RCC).
A new study revealed that researchers have found a genetic test that could help doctors determine which patients with multiple myeloma are at “ultra high risk” of their cancer progressing aggressively in its early stages.
A new study found that alternative swab materials and commonly available saline are effective for COVID-19 testing, allowing patients to self-administer tests.
The CDC's updated guidance for pharmacies during the COVID-19 pandemic is based on the most recent information regarding safety practices and precautions for the disease.
In a new study, researchers present their findings of a signaling pathway that could be used in patients with triple-negative breast cancer (TNBC) to enhance therapies in the future.
The antiviral drug remdesivir has been shown by researchers to effectively stop the replication mechanism of SARS-CoV-2 that causes COVID-19, according to a new study.
A new study investigated the molecular impact of the cancer-killing PARP-1 inhibitor (PARPi) binding to PARP-1 and found that the drug can be structurally modified to increase its power to kill tumor cells.
Vaccine skepticism, or a hesitancy or unwillingness to get vaccinated or to vaccinate one’s children, may be the result of some people overestimating the likelihood of negative events.
Researchers investigated the presence of coronaviruses in the bat population due to an understanding that coronaviruses can spread following a spillover from animals.
Chloroquine, hydroxychloroquine, and azithromycin are currently being evaluated as potential treatments for COVID-19, despite limited evidence to support the drugs’ efficacy.
Researchers presented findings in conjunction with the Society of Gynecologic Oncology 2020 Annual Meeting on Women’s Cancer on the phase 3 VELIA trial studying the safety of veliparib.
The kinase inhibitor selumetinib was approved for the treatment of pediatric patients aged 2 years and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.
Providers with access to COVID-19 tests have reported false-negative results for some patients, raising concerns about the limitations of tests as a source of reliable information.
Pain is the most common reason patients seek medical marijuana, yet patients' resulting consumption patterns of marijuana when treating pain may also have an effect on their health.
There have been reports of patients with COVID-19 having ST-segment elevation (STE) and, even after invasive coronary angiography, continuing to show no signs of COVID-19.
COA released a statement explaining that it fundamentally opposes home infusion of chemotherapy, cancer immunotherapy, and cancer treatment supportive drugs due to concerns regarding the safety of patients in such an environment.
Research explores the impact of obesity on prescription opioid use, investigating specifically the link between obesity and long-term prescription use.
The antiviral drug remdesivir was originally developed as a treatment for Ebola in 2014, but upon the surge of COVID-19, its use was investigated in treating COVID-19.
PittCoVacc produces antibodies specific to SARS-CoV-2 at quantities thought to be sufficient for neutralizing COVID-19 within 2 weeks.
School closures during the COVID-19 epidemic raises unique challenges regarding the benefits weighed against the costs of resulting health care worker absenteeism.
